{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:40:49Z","timestamp":1787496049925,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["# 21K1957"],"award-info":[{"award-number":["# 21K1957"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["#20H03817"],"award-info":[{"award-number":["#20H03817"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006724","name":"Japanese Urological Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006724","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and purpose<\/jats:title>\n                    <jats:p>Neoadjuvant chemotherapy (NAC) is a well-established standard practice in invasive bladder cancer (BCa), however patient selection remains challenging. High expression of vasohibin-1 (VASH1), an endogenous regulator of angiogenesis, has been reported in high-grade and advanced BCa; however, its prognostic value for chemotherapy outcomes remains unexplored. In this study, we sought to identify biomarkers of chemotherapy response focusing on the relationship between angiogenesis and tissue hypoxia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Forty Japanese patients with BCa who underwent NAC and radical cystectomy were included in the present analysis. We compared the immunohistochemical expression of CD34, VASH1, and carbonic anhydrase 9 (CA9) between patients who achieved tumor clearance at operation (ypT0) and those with residual disease after cystectomy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There were 19 patients in the ypT0 group, while the remaining 21 patients had residual tumors at operation. Patients in the ypT0 group had high microvessel density (\n                      <jats:italic>p\u00a0=<\/jats:italic>\n                      \u00a00.031), high VASH1 density (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001), and stronger CA9 staining (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.046) than their counterparts. Multivariate analysis identified microvessel and VASH1 density as independent predictive factors for pathological ypT0 disease (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.043 and 0.002, respectively). The 5-year recurrence-free survival rate was higher in the high VASH1 density group than in the low VASH1 density group (66.3% vs. 33.3%,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.036).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>VASH1 density is a potential therapeutic biomarker for chemotherapy response in BCa.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-024-15009-1","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T10:36:00Z","timestamp":1708425360000},"page":"2951-2958","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Vasohibin-1 Expression Can Predict Pathological Complete Remission of Advanced Bladder Cancer with Neoadjuvant Chemotherapy"],"prefix":"10.1245","volume":"31","author":[{"given":"Minami","family":"Omura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4371-4594","authenticated-orcid":false,"given":"Takeo","family":"Kosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Shigeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Saya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasufumi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Oya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"key":"15009_CR1","unstructured":"World Health Organization International Agency for Research on Cancer. 2020. Available at: https:\/\/gco.iarc.fr\/today\/online-analysis-table. Accessed 22 Feb 2023."},{"issue":"3","key":"15009_CR2","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.eururo.2003.10.006","volume":"45","author":"BP Schrier","year":"2004","unstructured":"Schrier BP, Hollander MP, van Rhijn BW, Kiemeney LA, Witjes JA. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol. 2004;45(3):292\u2013296. https:\/\/doi.org\/10.1016\/j.eururo.2003.10.006.","journal-title":"Eur Urol."},{"issue":"1","key":"15009_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","volume":"79","author":"JA Witjes","year":"2021","unstructured":"Witjes JA, Bruins HM, Cathomas R, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. EurUrol. 2021;79(1):82\u2013104.\u00a0https:\/\/doi.org\/10.1016\/j.eururo.2020.03.055.","journal-title":"EurUrol."},{"issue":"6","key":"15009_CR4","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","volume":"21","author":"M Yin","year":"2016","unstructured":"Yin M, Joshi M, Meijer RP, et al. Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis. Oncologist. 2016;21(6):708\u2013715.\u00a0https:\/\/doi.org\/10.1634\/theoncologist.2015-0440.","journal-title":"Oncologist."},{"issue":"1","key":"15009_CR5","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1038\/oncsis.2015.50","volume":"5","author":"KL Eales","year":"2016","unstructured":"Eales KL, Hollinshead KE, Tennant DA. Hypoxia and metabolic adaptation of cancer cells. Oncogenesis. 2016;5(1):e190. https:\/\/doi.org\/10.1038\/oncsis.2015.50.","journal-title":"Oncogenesis."},{"issue":"2","key":"15009_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/joim.12019","volume":"273","author":"L Claesson-Welsh","year":"2013","unstructured":"Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med. 2013;273(2):114\u2013127.\u00a0https:\/\/doi.org\/10.1111\/joim.12019.","journal-title":"J Intern Med."},{"issue":"6801","key":"15009_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/35025220","volume":"407","author":"P Carmeliet","year":"2000","unstructured":"Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249\u2013257. \u00a0https:\/\/doi.org\/10.1038\/35025220.","journal-title":"Nature"},{"issue":"6","key":"15009_CR8","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.clon.2021.03.001","volume":"33","author":"T Lodhi","year":"2021","unstructured":"Lodhi T, Song YP, West C, Hoskin P, Choudhury A. Hypoxia and its modification in bladder cancer: current and future perspectives. Clin Oncol (R Coll Radiol). 2021;33(6):376\u2013390.\u00a0https:\/\/doi.org\/10.1016\/j.clon.2021.03.001.","journal-title":"Clin Oncol (R Coll Radiol)."},{"issue":"21","key":"15009_CR9","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1093\/jnci\/87.21.1603","volume":"87","author":"BH Bochner","year":"1995","unstructured":"Bochner BH, Cote RJ, Weidner N, et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst. 1995;87(21):1603\u20131612. https:\/\/doi.org\/10.1093\/jnci\/87.21.1603.","journal-title":"J Natl Cancer Inst."},{"issue":"6","key":"15009_CR10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.5551\/jat.43398","volume":"25","author":"Y Sato","year":"2018","unstructured":"Sato Y. Double-face of vasohibin-1 for the maintenance of vascular homeostasis and healthy longevity. J Atheroscler Thromb. 2018;25(6):461\u2013466. https:\/\/doi.org\/10.5551\/jat.43398.","journal-title":"J Atheroscler Thromb."},{"issue":"7","key":"15009_CR11","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1172\/JCI21152","volume":"114","author":"K Watanabe","year":"2004","unstructured":"Watanabe K, Hasegawa Y, Yamashita H, et al. Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J Clin Investig. 2004;114(7):898\u2013907. https:\/\/doi.org\/10.1172\/JCI21152.","journal-title":"J Clin Investig"},{"issue":"19","key":"15009_CR12","doi-asserted-by":"publisher","first-page":"4810","DOI":"10.1182\/blood-2008-07-170316","volume":"113","author":"H Kimura","year":"2009","unstructured":"Kimura H, Miyashita H, Suzuki Y, et al. Distinctive localization and opposed roles of vasohibin-1 and vasohibin-2 in the regulation of angiogenesis. Blood. 2009;113(19):4810\u20134818.\u00a0https:\/\/doi.org\/10.1182\/blood-2008-07-170316.","journal-title":"Blood."},{"issue":"4","key":"15009_CR13","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.3892\/etm.2017.4969","volume":"14","author":"B Zhang","year":"2017","unstructured":"Zhang B, Wu Z, Xie W, et al. The expression of vasohibin-1 and its prognostic significance in bladder cancer. Exp Ther Med. 2017;14(4):3477\u20133484. https:\/\/doi.org\/10.3892\/etm.2017.4969.","journal-title":"Exp Ther Med."},{"issue":"5","key":"15009_CR14","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.eururo.2017.04.015","volume":"72","author":"V Soukup","year":"2017","unstructured":"Soukup V, \u010capoun O, Cohen D, et al. Prognostic performance and reproducibility of the 1973 and 2004\/2016 World Health Organization grading classification systems in non-muscle-invasive bladder cancer: A European Association of Urology non-muscle invasive bladder cancer guidelines panel systematic review. Eur Urol. 2017;72(5):801\u2013813. \u00a0https:\/\/doi.org\/10.1016\/j.eururo.2017.04.015.","journal-title":"Eur Urol."},{"issue":"7","key":"15009_CR15","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1002\/cncr.24163","volume":"115","author":"T Klatte","year":"2009","unstructured":"Klatte T, Seligson DB, Rao J, et al. Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker. Cancer. 2009;115(7):1448\u20131458. \u00a0https:\/\/doi.org\/10.1002\/cncr.24163.","journal-title":"Cancer."},{"issue":"2","key":"15009_CR16","first-page":"51","volume":"80","author":"JE Ziello","year":"2007","unstructured":"Ziello JE, Jovin IS, Huang Y. Hypoxia-inducible factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. Yale J Biol Med. 2007;80(2):51\u201360.","journal-title":"Yale J Biol Med"},{"issue":"12","key":"15009_CR17","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1177\/1947601911423654","volume":"2","author":"BL Krock","year":"2011","unstructured":"Krock BL, Skuli N, Simon MC. Hypoxia-induced angiogenesis: good and evil. Genes Cancer. 2011;2(12):1117\u20131133. https:\/\/doi.org\/10.1177\/1947601911423654.","journal-title":"Genes Cancer."},{"issue":"6","key":"15009_CR18","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nm0603-685","volume":"9","author":"RK Jain","year":"2003","unstructured":"Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003;9(6):685\u2013693.  https:\/\/doi.org\/10.1038\/nm0603-685.","journal-title":"Nat Med."},{"issue":"3","key":"15009_CR19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/s0092-8674(00)80108-7","volume":"86","author":"D Hanahan","year":"1996","unstructured":"Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86(3):353\u2013364. \u00a0https:\/\/doi.org\/10.1016\/s0092-8674(00)80108-7.","journal-title":"Cell"},{"issue":"1","key":"15009_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/metabo8010002","volume":"8","author":"E Iessi","year":"2017","unstructured":"Iessi E, Logozzi M, Mizzoni D, et al. Rethinking the combination of proton exchanger inhibitors in cancer therapy. Metabolites. 2017;8(1):2.\u00a0https:\/\/doi.org\/10.3390\/metabo8010002.","journal-title":"Metabolites."},{"key":"15009_CR21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.semcancer.2017.01.008","volume":"43","author":"I Kolosenko","year":"2017","unstructured":"Kolosenko I, Avnet S, Baldini N, Viklund J, De Milito A. Therapeutic implications of tumor interstitial acidification. Semin Cancer Biol. 2017;43:119\u2013133. \u00a0https:\/\/doi.org\/10.1016\/j.semcancer.2017.01.008.","journal-title":"Semin Cancer Biol."},{"issue":"6","key":"15009_CR22","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3233\/CBM-140417","volume":"14","author":"J Huang","year":"2014","unstructured":"Huang J, Ma X, Chen X, et al. Microvessel density as a prognostic factor in bladder cancer: a systematic review of literature and meta-analysis. Cancer Biomark. 2014;14(6):505\u2013514. \u00a0https:\/\/doi.org\/10.3233\/CBM-140417.","journal-title":"Cancer Biomark."},{"issue":"6","key":"15009_CR23","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1161\/01.RES.0000182903.16652.d7","volume":"97","author":"A Armulik","year":"2005","unstructured":"Armulik A, Abramsson A, Betsholtz C. Endothelial\/pericyte interactions. Circ Res. 2005;97(6):512\u2013523. \u00a0https:\/\/doi.org\/10.1161\/01.RES.0000182903.16652.d7.","journal-title":"Circ Res."},{"key":"15009_CR24","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/1471-2407-9-284","volume":"9","author":"J Kern","year":"2009","unstructured":"Kern J, Steurer M, Gastl G, Gunsilius E, Untergasser G. Vasohibin inhibits angiogenic sprouting in vitro and supports vascular maturation processes in vivo. BMC Cancer. 2009;9:284.\u00a0https:\/\/doi.org\/10.1186\/1471-2407-9-284.","journal-title":"BMC Cancer."},{"issue":"15","key":"15009_CR25","doi-asserted-by":"publisher","first-page":"4145","DOI":"10.1158\/1078-0432.CCR-12-0073","volume":"18","author":"Y Miyazaki","year":"2012","unstructured":"Miyazaki Y, Kosaka T, Mikami S, et al. The prognostic significance of vasohibin-1 expression in patients with upper urinary tract urothelial carcinoma. Clin Cancer Res. 2012;18(15):4145\u20134153. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0073.","journal-title":"Clin Cancer Res."},{"issue":"8","key":"15009_CR26","doi-asserted-by":"publisher","first-page":"498.e1","DOI":"10.1016\/j.urolonc.2021.04.011","volume":"39","author":"T Todenh\u00f6fer","year":"2021","unstructured":"Todenh\u00f6fer T, Gibb EA, Seiler R, et al. Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma.\u00a0Urol Oncol. 2021;39(8):498.e1\u2013498.e11.\u00a0https:\/\/doi.org\/10.1016\/j.urolonc.2021.04.011.","journal-title":"Urol Oncol."},{"issue":"7","key":"15009_CR27","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/sj.bjc.6601260","volume":"89","author":"PJ Hoskin","year":"2003","unstructured":"Hoskin PJ, Sibtain A, Daley FM, Wilson GD. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer. 2003;89(7):1290\u20131297. \u00a0https:\/\/doi.org\/10.1038\/sj.bjc.6601260.","journal-title":"Br J Cancer."},{"issue":"5","key":"15009_CR28","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1177\/11206721211073403","volume":"32","author":"Y Feng","year":"2022","unstructured":"Feng Y, Wang D, Liu Y, Pang X, Zhang H. Serum levels of vasohibin-1 in type 2 diabetes mellitus patients with diabetic retinopathy. Eur J Ophthalmol. 2022;32(5):2864\u20132869.  https:\/\/doi.org\/10.1177\/11206721211073403.","journal-title":"Eur J Ophthalmol."},{"issue":"12","key":"15009_CR29","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S1470-2045(22)00613-1","volume":"23","author":"HM Kuerer","year":"2022","unstructured":"Kuerer HM, Smith BD, Krishnamurthy S, et al. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2022;23(12):1517\u20131524.\u00a0https:\/\/doi.org\/10.1016\/S1470-2045(22)00613-1.","journal-title":"Lancet Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15009-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-15009-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15009-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T12:10:17Z","timestamp":1712319017000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-15009-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["15009"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-15009-1","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,20]]},"assertion":[{"value":"28 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Minami Omura, Takeo Kosaka, Hiroaki Kobayashi, Keisuke Shigeta, Kazuhiro Matsumoto, Satoshi Hara, Eiji Kikuchi, Shuji Mikami, Hideyuki Saya, Yasufumi Sato, and Mototsugu Oya declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}